Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
0.9500
-0.0800 (-7.77%)
At close: May 13, 2025, 4:00 PM
0.9312
-0.0188 (-1.98%)
Pre-market: May 14, 2025, 6:40 AM EDT
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,686,361
Market Cap
41.80M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
QNCX News
- 23 hours ago - Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - Business Wire
- 13 days ago - Quince Therapeutics to Present at Citizens Life Sciences Conference - Business Wire
- 5 weeks ago - Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - Business Wire
- 7 weeks ago - Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
- 3 months ago - Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 3 months ago - Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire